RUDN Journal of Medicine (Mar 2012)

Clinical trial of fibrinselective thrombolytic pharmaceutical agent «FORTELYZIN®» (III Phase)

  • S S Markin,
  • A M Semenov,
  • V A Markov,
  • A A Nizov,
  • E A Ponomarev,
  • P A Lebedev

Journal volume & issue
Vol. 0, no. 1
pp. 105 – 110

Abstract

Read online

The clinical trial of fibrinselective thrombolytic agent Fortelyzin® (III phase) showed the comparative efficacy and safety with Actilyse® in patients with acute myocardial infarction and obtained data permitted to recommend it for clinical usage.

Keywords